The massive overhang of registered shares (~189% of float) will likely pressure VBIO's stock price as the market prices in potential selling by 3i. Watch for any 8-K filing indicating 3i has begun selling shares, which would trigger further downside. The deeply out-of-the-money conversion price ($3.62 vs $1.55 close) means near-term conversion is unlikely unless the stock rallies significantly.
Price Chart
Executive Summary
Valion Bio filed an S-3 registration statement to register up to 3,954,381 shares of common stock for resale by its sole selling stockholder, 3i, LP. The shares are issuable upon conversion of Series B and Series C preferred stock and exercise of warrants, representing ~189% dilution relative to the 2,095,687 shares outstanding as of October 13, 2026. The company will not receive any proceeds from the resale, only from warrant exercises if they occur.
Key Facts
- Registers up to 3,954,381 shares for resale by 3i, LP — ~189% of the 2,095,687 shares outstanding as of October 13, 2026
- Shares consist of: 536,159 from Series B preferred conversion, 2,308,780 from Series C preferred conversion, and 1,109,442 from warrant exercises
- Conversion prices are fixed at $3.62 per share for both Series B and Series C preferred; stock closed at $1.55 on October 13, 2026 — deeply out-of-the-money
- Company receives no proceeds from resale; only from warrant exercises (if any), which are unlikely given $1.55 stock price vs. $3.62 conversion price
- Auditor's report contains a going-concern explanatory paragraph
- 3i, LP also holds a senior secured note of $15,916,188.81 convertible into up to 4,396,737 additional shares
- Reverse stock split of 1-for-25 executed on August 31, 2026
Financial Impact
Potential dilution of ~189% from the registered shares alone; 3i's total beneficial ownership pre-offering is 9,142,842 shares (436% of outstanding), including a $15.9M convertible note
Risk Factors
- Massive dilution risk — registered shares represent ~189% of current outstanding shares
- Going-concern uncertainty flagged by auditor — company may need additional capital
- 3i holds a $15.9M convertible note that could add further dilution
- Stock price well below conversion price — warrants and preferred conversions unlikely to generate cash for the company
- Reverse stock split suggests Nasdaq listing compliance concerns
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001683168-26-007936 |
| Document: valion_ex107.htm | 0001683168-26-007936 |
| Document: valion_ex0501.htm | 0001683168-26-007936 |
| Document: valion_ex2301.htm | 0001683168-26-007936 |
| Document: 0001683168-26-007936-index-headers.html | 0001683168-26-007936 |
| Document: 0001683168-26-007936-index.html | 0001683168-26-007936 |
| Document: 0001683168-26-007936.txt | 0001683168-26-007936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.8400 (+6.15%) |
Oct 26, 2026 today | 8-K | $1.15 | awaiting T+20 | — | $0.8400 (−26.70%) |
Oct 22, 2026 4d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.8400 (−12.13%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8400 (+25.00%) |
Oct 21, 2026 6d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.8400 (+25.00%) |
Oct 16, 2026 10d ago | S-3 | $1.16 | awaiting T+20 | — | $0.8400 (+27.59%) |
Oct 16, 2026 10d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.8400 (+27.59%) |
Oct 15, 2026 11d ago | 8-K | $1.23 | awaiting T+20 | — | $0.8400 (−31.71%) |
Oct 14, 2026 12d ago | 8-K | $1.45 | awaiting T+20 | — | $0.8400 (−42.07%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.8400 (+61.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers